## Ifw ,

## CERTIFICATE OF MAILING

AUG 14 2006 B

I hereby certify that this correspondence is being deposited with the United States Postal ervice with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop <u>Disclosure</u> Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

Date: 8 10 2006

Winsome A. St. Rose

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Frank Bergmann, et al. ) EXAMINER: David C. Thomas

SERIAL NO.: 10/540,406 ) ART UNIT: 1637

FILED: June 24, 2005 ) Confirmation No. 8359

FOR: METHOD FOR BISULFITE ) DOCKET NO: 21581-US

**TREATMENT** 

## INFORMATION DISCLOSURE STATEMENT

Mail Stop <u>Disclosure</u>. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

2

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: 8/10/06

Reg. No. 39,175

**Correspondence Address:** Roche Molecular Systems, Inc 1145 Atlantic Avenue

Alameda, CA 94501 Tele: (510) 814-2800

Fax: (510) 814-2973

		•	mmerce Patent and Tradema			Atty.	Docket No. 21581	-US	Sei	rial No. 10/54	0,406	
	OFF E	F <b>OR</b> Use s	MATION CITED BY A several sheets if necessary	PPLI(	CANT	Appli	cants: Frank Berg	gmann	, et	al.		
	AUG 14 2006		•			Filing	Date: <b>June 24, 2</b> 0	)05		Group: 1637	7	
周	ξ/			I	U.S. PAT	ENT D	OCUMENTS					
Y	EXAMPLE OF		DOCUMENT NUMBER	ISS	UE DATE		NAME	CLA	ss	SUBCLASS		DATE OPRIATE
		1	4,683,202	07	7/28/87	,	Mullis, et al.	43	5	91	10/2	25/85
		2	5,130,238	07	7/14/92		Malek, et al.	43	5	91	08/2	3/89
		3	5,137,806	08	8/11/92		LeMaistre, et al	43	5	6	12/1	.1/89
		4	5,210,015	0	5/11/93		Gelfand, et al	43	5	6	08/0	06/90
		5	5,234,809	08	8/10/93		Boom, et al	43	5	91	07/0	)1/91
		6	5,487,972	0	1/30/96		Gelfand, et al	43	5	6	01/0	05/93
		7	5,552,277	0	9/03/96		Nelson, et al	43	5	6	07/1	.9/94
i		8	5,595,890	0	1/21/97		Newton, et al	43	5	91.2	02/1	.7/95
		9	5,639,611		6/17/97		Wallace, et al	43	5	6	11/0	)9/94
		10	5,786,146	0	7/28/98		Herman, et al	43	5	6	01/0	03/96
		11	5,804,375	0	9/08/98		Gelfand, et al	43	5	6	04/2	25/95
		12	6,174,670 B1	0	1/16/01		Wittwer, et al	43	5	6		)4/97
		13	6,331,393 B1		2/18/01		Laird, et al	43	5	6	05/1	14/99
				FO			Γ DOCUMENTS					
			DOCUMENT NUMBER		PUBLICA DAT		COUNTRY	CLA	SS	SUBCLASS	TRANS	LATION
		14	0 200 362 B1		12/10	/86	EP					
		15	0 201 184 B1		12/17	/86	EP					
		16	0 389 063 B1		09/26	/90	EP					
		17	0 439 182 B1		07/31	/91	EP					
		18	1 394 172 A1		03/03	/04	EP					
		19	WO 90/01069		02/08	/90	PCT		-			
		20	WO 92/008800		01/23	/92			-			
		21	WO 92/02638		02/20	/92	PCT					
		22	WO 96/41811		12/27	/96	PCT					
	-	23	WO 99/16781		04/08	/99	PCT					
		24	WO 99/40098		08/12	/99	PCT					
		25	WO 00/32762		06/08	/00	PCT					

Attorney Docket: 21581-US Serial No. 10/540,406 Filing Date: June 24, 2005 Page 2 of 3

	26	WO 00/37291	06/29/00	РСТ							
	27	WO 01/37291 A1	05/25/01	PCT							
	28	WO 01/98528 A2	12/27/01	PCT							
	29	WO 02/31186 A2	04/18/02	PCT							
	+						<del> </del>	<u> </u>			
			<u> </u>								
	·	OTHER ART (Inc						-			
	30	4:41-47									
31 Alderton, R., et al., 1992, "Magnetic Bead Purification of M13 DNA Sequencing Templat Biochemistry, 201:166-169								ical			
·	32 Ausubel F., et al., 2001, "Current Protocols In Molecular Biology", John Wiley & Sons, Inc., Sup										
	56:1-10										
	33										
	34	1									
	ļ	Proc. Natl. Acad. Sci. USA, 88:189-193									
•	35	Benyajati, C., et al., "Alcohol dehydrogenase in Drosophila: isolation and characterization of messenger									
	36	RNA and eDNA clone", Nucleic Acids Research, 8:5649-5667									
	36	6 Clark, S., et al., 1994, "High sensitivity mapping of methylated cytosines", Nucleic Acids Research,  22(15):2990-2997									
	37	Feil, R., et al., 1994, "Methylation analysis on individual chromosomes: improved protocol for bisulphate									
		genomic sequencing", Oxford University Press, 22(4):695-696									
Frommer, M., 1992, "A genomic sequencing protocol that yields a positive display of residues in individual DNA strands", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1827-1831							5-methylcytosine				
	39		4, "Sequencing 5-Methylcytosine Residues in Genomic DNA", BioEssays, 16(6):431436								
	40 Grigg, G., 1996, "Sequencing 5-methylcytosine residues by the bisulphate method", The Journal of										
		Seq.&Mapping 6:189-198									
	41	Grunau, C., et al., 2001, "Bisulfite genomic sequencing: systematic investigation of critical experimental									
		parameters", Nucleic Acids Research, 29 (13e65):1-7									
	42	1									
		modeled after retroviral re	plication", Proc. N	atl. Acad. Sci. USA	, <b>87:</b> 1874-187	8					
	43	Hayatsu, H., et al., 1970, "T	he Addition of So	dium Bisulfite to	Uracil and th	e Cytosine", J	ournal of	the			
		American Chemical Society, S	<b>2</b> ( <u>3</u> ):724-726			<u></u>					
	44	Hayatsu, H., et al., 1970, "F		n Bisulfite with Ur	acil, Cytosir	e, and their D	erivative	s",			
		Biochemisrty 9 (14): 2858-28			D: 10: I	1 175 1	<u></u>				
	45	Komlyama, M., et al., 1994, Cytosine in Oligodeoxyrib					nation of				
46 Kubareva, E., et al., 2002, "Determination of Methylation Site of DNA-Methyltr					yltransferase nlaX by a Hybrid						
		Method', BioTechniques 33:									
	47	Kwoh, D., et al., 1989, "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format", <i>Proc. Natl. Acad. Sci.</i>									
		USA, <b>86:</b> 1173-1177									

Attorney Docket: 21581-US Serial No. 10/540,406 Filing Date: June 24, 2005 Page 3 of 3

	48	Oakeley, E., 1999, "DNA methylation analysis: a review of current methodologies", Pharmacology &					
		Therapeutics, <b>84:</b> 389-400					
	49	Olek, A., et al., 1996, "A modified and improved method for bisulphate based cytosine methylation analysis", Nucleic Acids Research, 24(24):5064-5066					
	50	Paulin, R., et al., 1998, "Urea improves efficiency of bisulphate-mediated sequencing of 5'-methylcytosine in genomic DNA", Nucleic Acids Research, 26(21):5009-5010					
	751 Raizis, A., et al., 1995, "A Bisulfite method of 5-Methylcytosine Mapping That Minimizes Templa Degradation", Analytical Biochemistry, 226:161-166						
	52	Sabban, E., et al., 1982, "The Effect of Bisulfite-induced C→U Transitions on Aminoacylation of Escherichi coli Glycine tRNA', The Journal of Biological Chemistry, 257 (9) 4796-4805					
	53	Slae, S, et al., 1978, "Deamination of Cytidine by Bisulfite: Mechanism at Neutral pH", J Org Chem., 43 (21):497-4200					
	54	Whelen, A., et al., 1996, "The Role of Nucleic Acid Amplification and Detection in the Clinical Microbiology Laboratory", <i>Annu. Rev. Microbid</i> , <b>50:</b> 349-379					
Wu, D., et al., 1989, "The Ligation Amplification Reaction (LAR) - Amplification of Specific DN Sequences Using Sequential Rounds of Template-Dependent Ligation							
EXAMINER6	l	DATE CONSIDERED					
*EXAMINER	Initia	al if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in					

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.